# Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06896890/  
OnCo record `nct06896890` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CIS-DPI in non-small-cell lung cancer, run by Inhatarget Therapeutics, now recruiting.

## Summary

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06896890 by Inhatarget Therapeutics, with 32 participants planned, started 2023-06-23 and due to reach its primary completion in 2026-10-01. Interventions recorded: CIS-DPI.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06896890
- Phase: 1/2
- Setting: A Phase I/II First-in-human Trial Investigating Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Dry Powder Cisplatin Formulation for Inhalation to Treat Stage IV Non-small Cell Lung Cancer Patients
- Sponsor: Inhatarget Therapeutics
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT06896890: https://clinicaltrials.gov/study/NCT06896890

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06896890.json